Lung cancer kills more than 1.5 million patients worldwide each year.1 Roughly 85% of all lung malignancies are non-small cell lung cancers (NSCLC), which mostly consist of adenocarcinoma (AdC) and squamous cell carcinoma (SCC) histotypes.2 Although there are several targeted lung cancer treatments for AdC including the EGFR TKI inhibitors, inhibitors of abnormal ALK and several antibodies among others,3 only a few have recently been approved for SCC, including a monoclonal antibody against EGFR, Necitumumab4 and immune checkpoint inhibitors Nivolumab5 and Pembrolizumab.6 This evidence concerns the gene EGFR and lung carcinoma.